Arrowhead price target raised to $17 from $11 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff noted that Arrowhead presented preliminary Phase 1 data on ARO-AAT that he was encouraged by and he anticipates the company could begin a robust Phase 2 study in AAT liver disease patients next year. Given his increased estimates for the value of ARO-AAT and ARO-HBV, Tenthoff raised his price target on Arrowhead shares to $17 and reiterated an Overweight rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.